These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 30024924

  • 1. Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial.
    Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, Vandebosch A, Van der Elst W, Molenberghs G, Alonso A.
    PLoS One; 2018; 13(7):e0200539. PubMed ID: 30024924
    [Abstract] [Full Text] [Related]

  • 2. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
    Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group.
    N Engl J Med; 2014 Aug 21; 371(8):723-32. PubMed ID: 25140958
    [Abstract] [Full Text] [Related]

  • 3. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, SimpliciTB Consortium.
    Lancet Infect Dis; 2024 Sep 21; 24(9):1003-1014. PubMed ID: 38768617
    [Abstract] [Full Text] [Related]

  • 4. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 5. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV, Estrada SJ.
    Pharmacotherapy; 2014 Nov 25; 34(11):1187-97. PubMed ID: 25203970
    [Abstract] [Full Text] [Related]

  • 6. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group.
    Eur Respir J; 2016 Feb 25; 47(2):564-74. PubMed ID: 26647431
    [Abstract] [Full Text] [Related]

  • 7. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.
    N Engl J Med; 2012 Jun 07; 366(23):2151-60. PubMed ID: 22670901
    [Abstract] [Full Text] [Related]

  • 8. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia.
    Shibabaw A, Gelaw B, Wang SH, Tessema B.
    PLoS One; 2018 Jun 07; 13(6):e0198080. PubMed ID: 29944658
    [Abstract] [Full Text] [Related]

  • 9. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
    Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V.
    Ann Intern Med; 2006 May 02; 144(9):650-9. PubMed ID: 16670134
    [Abstract] [Full Text] [Related]

  • 10. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, Agustin H, Isbaniah F, Dowdy DW.
    Int J Tuberc Lung Dis; 2014 May 02; 18(5):564-70. PubMed ID: 24903794
    [Abstract] [Full Text] [Related]

  • 11. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, Rich ML, Zarli K, Samieva N, Oyewusi L, Nair P, Mudassar M, Melikyan N, Lenggogeni P, Lecca L, Kumsa A, Khan M, Islam S, Hussein K, Docteur W, Chumburidze N, Berikova E, Atshemyan H, Atwood S, Alam M, Ahmed S, Bastard M, Mitnick CD.
    Am J Respir Crit Care Med; 2021 Jan 01; 203(1):111-119. PubMed ID: 32706644
    [Abstract] [Full Text] [Related]

  • 12. The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
    Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF.
    N Engl J Med; 2009 Jun 04; 360(23):2397-405. PubMed ID: 19494215
    [Abstract] [Full Text] [Related]

  • 13. Predictors of early and interim culture un-conversion in multidrug-resistant/rifampicin-resistant tuberculosis: a retrospective multi-center cohort study in China.
    Chen Q, He W, Du J, Kang W, Zou L, Tang X, Tang P, Guo C, Pan Q, Zhu Q, Yang S, Guo Z, Wu G, Tang S.
    Antimicrob Resist Infect Control; 2024 Oct 15; 13(1):126. PubMed ID: 39407338
    [Abstract] [Full Text] [Related]

  • 14. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB, Karaoui LR, Mansour H.
    Ann Pharmacother; 2014 Jan 15; 48(1):107-15. PubMed ID: 24259600
    [Abstract] [Full Text] [Related]

  • 15. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J, Gao M, Du J, Pang Y, Mao G, Lounis N, Bakare N, Jiang Y, Zhan Y, Liu Y, Li L, Trial Team.
    Trials; 2024 Apr 01; 25(1):227. PubMed ID: 38561815
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis.
    Alene KA, Viney K, Yi H, McBryde ES, Yang K, Bai L, Gray DJ, Xu Z, Clements ACA.
    PLoS One; 2018 Apr 01; 13(5):e0197880. PubMed ID: 29791488
    [Abstract] [Full Text] [Related]

  • 17. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, Pei Y, Li G, Liu Y, Shu W, Fan L, Wu Q, Du J, Chen X, Tang P, Xiong Y, Li M, Cai Q, Jin L, Mei Z, Pang Y, Li L.
    Clin Microbiol Infect; 2021 Apr 01; 27(4):597-602. PubMed ID: 32553880
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.
    Lancet Respir Med; 2019 Mar 01; 7(3):249-259. PubMed ID: 30630778
    [Abstract] [Full Text] [Related]

  • 19. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China.
    Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X, Zhu L.
    BMC Infect Dis; 2018 Mar 06; 18(1):114. PubMed ID: 29510666
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, Patel Y, Mehandru L, Jaju J, Ponnuraja C, Gupta M, Kalaiselvan V, Shamim A, Khaparde S, Swaminathan S, Bedaquiline CAP Site Teams.
    Indian J Tuberc; 2020 Jan 06; 67(1):29-37. PubMed ID: 32192613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.